Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems, Inc. (INSP) is a pioneering medical technology company headquartered in Maple Grove, Minnesota. Specializing in the development and commercialization of innovative, minimally invasive solutions, Inspire focuses on providing effective treatments for patients with obstructive sleep apnea (OSA). The company's flagship product, the Inspire system, is a revolutionary neurostimulation technology designed to safely and effectively treat moderate to severe OSA.
Inspire operates primarily across the United States and Europe, with the bulk of its revenue generated from the U.S. market. The company has seen significant growth, reporting a 65% increase in year-over-year revenue for the second quarter of 2023, reaching $151.1 million. This growth is attributed to increased utilization at existing sites, the addition of 72 new implanting centers, and 19 new U.S. sales territories.
In recent business highlights, Inspire has achieved several key milestones. These include the submission of the Inspire V neurostimulation PMA supplement application to the FDA and receiving two critical FDA approvals which expand the upper limit of the Apnea-Hypopnea Index (AHI) to 100 events per hour from 65 and raise the BMI warning in the labeling to 40 from 32. Additionally, Inspire received approval for its SleepSync™ physician programmer. These advancements are expected to enhance the company’s product offerings and market reach.
Financially, Inspire ended the second quarter of 2023 with a gross margin of 83.9% and operating expenses of $143.4 million, reflecting ongoing investments in U.S. sales expansion, direct-to-patient marketing, and product development. Despite a net loss of $12.0 million for the quarter, this marks an improvement from the $14.5 million loss in the same period the prior year.
Looking ahead, Inspire has increased its full-year 2023 revenue guidance to between $600 million and $610 million, reflecting a growth of 47% to 50% over the previous year. The company is committed to opening new medical centers and expanding its U.S. territories, anticipating sustained organic growth driven by its innovative therapies and strengthened leadership team.
For current updates and detailed information about Inspire Medical Systems, visit inspiresleep.com.
Inspire Medical Systems (NYSE: INSP) reported strong Q4 2024 financial results with revenue reaching $239.7 million, up 25% year-over-year, and full-year revenue of $802.8 million, a 28% increase from 2023. The company achieved a gross margin of 85.0% in Q4 2024 and reported net income of $35.2 million with diluted EPS of $1.15.
Key operational highlights include the activation of 72 new U.S. centers, bringing the total to 1,435 medical centers, and the creation of 12 new sales territories, totaling 335 in the U.S. Operating cash flow for 2024 reached $130.2 million. The company initiated a $75 million accelerated share repurchase program and surpassed 90,000 patients treated with Inspire therapy.
For 2025, Inspire reaffirms revenue guidance of $940-955 million (17-19% growth) and introduces diluted EPS guidance of $2.10-2.20.
Inspire Medical Systems (NYSE: INSP) announced preliminary Q4 2024 revenue of $239.5-239.7 million, up 25% year-over-year, and full-year 2024 revenue of $802.6-802.8 million, representing 28% growth. The company provided initial 2025 revenue guidance of $940-955 million, projecting 17-19% growth.
Key operational highlights include activating 72 new U.S. centers in Q4, reaching 1,435 total implanting centers, and creating 12 new sales territories, totaling 335. The company successfully launched the Inspire V neurostimulator with over 40 implants in Singapore and the U.S.
Organizational changes include appointing Jason Kelly as Chief Manufacturing and Quality Officer, Carlton Weatherby expanding to Chief Strategy and Growth Officer, Randy Ban transitioning to EVP of Patient Access and Therapy Development, and new roles for Ivan Lubogo and Joe Sander in strategic and U.S. sales leadership.
Inspire Medical Systems (NYSE: INSP) has announced it will release its fourth quarter and fiscal 2024 financial results after market close on Monday, February 10, 2025. The company's management will host a conference call at 5:00 p.m. Eastern Time to discuss financial results and recent business developments.
The earnings call will be accessible through two options: a webcast via the company's Investor Relations page for those planning to listen only, and a separate registration link for participants who wish to ask questions. Participants planning to ask questions are advised to register at least 10 minutes before the call. A replay will be available on the Investor Relations website approximately two hours after the event and will remain archived for two weeks.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to present on Monday, January 13, 2025, at 11:15 a.m. Eastern Time.
The presentation will be available through a live webcast, with replay access remaining available for two weeks afterward in the Event Archive section of Inspire's Investor website at investors.inspiresleep.com.
Presidio Medical has appointed Richard J. Buchholz to its Board of Directors. Buchholz currently serves as Chief Financial Officer of Inspire Medical Systems (NYSE: INSP), where he has been instrumental in driving strategic financial and operational growth.
With extensive experience in healthcare finance, including previous CFO roles at superDimension and Vascular Solutions, Buchholz brings valuable expertise to Presidio Medical, a clinical stage company developing neuromodulation platforms. The appointment aligns with Presidio's strategy to strengthen its leadership team as it advances through key growth and development stages.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 12:00 p.m. Eastern Time. Interested parties can access the presentation through a live webcast, with replays available for two weeks afterward on the company's investor website at investors.inspiresleep.com.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 20, 2024, at 7:30 a.m. Eastern Time. Interested parties can access the presentation through a live webcast, with replays available for two weeks afterward on the company's investor website at investors.inspiresleep.com.
Inspire Medical Systems has initiated a $75 million accelerated share repurchase (ASR) program with Goldman Sachs, as part of its previously announced $150 million share repurchase authorization. The ASR transaction is scheduled to conclude in Q1 2025. The company's decision reflects confidence in its long-term growth potential, supported by strong revenue and earnings growth. The broader repurchase program, set to expire on August 5, 2026, allows for flexible implementation through various transaction methods and can be modified or discontinued at the company's discretion.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 20, 2024, at 11:00 a.m. Eastern Time. Interested parties can access the presentation through a live webcast, with replay availability for two weeks afterward on the company's investor website at investors.inspiresleep.com.
Inspire Medical Systems reported strong Q3 2024 financial results with revenue of $203.2 million, up 33% year-over-year. The company achieved a gross margin of 84.1% and generated operating income of $14.3 million. Earnings per share reached $0.60, compared to a loss of $0.29 in the prior year period.
The company activated 66 new U.S. centers and created 13 new sales territories, bringing totals to 1,371 centers and 323 territories. Based on strong performance, Inspire raised its full-year 2024 revenue guidance to $793-798 million and increased EPS guidance to $1.20-1.40.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
What is Inspire Medical Systems, Inc.?
What is the Inspire system?
What recent milestones has Inspire achieved?
How did Inspire perform financially in the second quarter of 2023?
What is the revenue guidance for Inspire in 2023?
Where does Inspire generate most of its revenue?
What are the key elements of Inspire's growth strategy?
Who is the CEO of Inspire Medical Systems?
What is the significance of the SleepSync™ physician programmer?
How many new implanting centers did Inspire add in the second quarter of 2023?
